Evidence map›Paper›PMID 33202066›Full record

Trial reportJournal of clinical pharmacology2021

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients.

Michael L Schmitz, Christopher M Rubino, Nikolas J Onufrak, Diana Valencia Martinez, Diane Licursi, Angela Karpf, Wes Cetnarowski

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05205486 (A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of a Single 3 Gram Dose of Cefazolin in Adult Subjects Weighing >= 120 kg Scheduled for Surgery), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05205486 phase1completednot on this mapstarted 2022, after this paper: background citation

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of a Single 3 Gram Dose of Cefazolin in Adult Subjects Weighing >= 120 kg Scheduled for Surgery

TypeinterventionalSponsorB. Braun Medical Inc.Ran2022 to 2023Enrolled12ConditionsInfectionsArmsCefazolin 3gm for Injection USP and Dextrose Injection USP
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Michael L SchmitzArkansas Children's Hospital, Little Rock, Arkansas, USA.
Christopher M RubinoInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Nikolas J OnufrakInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Diana Valencia MartinezB. Braun Medical Inc., Allentown, Pennsylvania, USA.
Diane LicursiB. Braun Medical Inc., Allentown, Pennsylvania, USA.
Angela KarpfB. Braun Medical Inc., Allentown, Pennsylvania, USA.
Wes CetnarowskiB. Braun Medical Inc., Allentown, Pennsylvania, USA.
B. Braun (United States) · USArkansas Children's Hospital · USInstitute for Clinical Pharmacodynamics (United States) · USUniversity at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefazolin is an antibiotic frequently used for perioperative prophylaxis. Data from healthy adults and pediatric surgery patients were pooled to refine a previously developed population pharmacokinetic (PK) model and to determine the optimal body weight cutoff for selecting fixed doses of either 1 or 2 g cefazolin to produce exposures in pediatric surgery patients similar to a single 2-g dose in adults. Regardless of dose used, cefazolin was well tolerated in pediatric patients. A total of 1102 plasma samples from 62 patients from 3 studies were available to assess the previous model. The pooled data set allowed for simplification of the model such that allometrically scaled clearance and volume parameters were found to provide a robust fit while removing unnecessary covariate relationships. Monte Carlo simulations using the final cefazolin population PK model suggested an optimal weight cutoff of 50 kg, in contrast to the previously suggested 60 kg for a single 2-g dose. Patients at or above this 50-kg cutoff would receive a 2-g dose of cefazolin, and those below 50 kg but ≥25 kg would receive a 1-g dose of cefazolin.

Indexed as

AdolescentAdultAgedAnti-Bacterial AgentsAntibiotic ProphylaxisArea Under CurveBody WeightCefazolinChildChild, PreschoolDose-Response Relationship, DrugFemaleHalf-LifeHumansMaleMetabolic Clearance RateAnti-Bacterial AgentsCefazolincefazolinmodel-based simulationspharmacokineticssurgical prophylaxis

Identifiers

PMID33202066
PMCPMC8049034
OpenAlexW3104189891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.